Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 3
1966 2
1967 2
1968 2
1971 3
1973 2
1974 1
1978 1
1991 1
1993 1
1998 1
1999 1
2012 1
2013 2
2014 1
2016 1
2017 1
2019 4
2020 1
2021 2
2022 2
2023 4
2024 3
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Effect of N-Acetylcysteine on Bronchiectasis in a Real-life Study. Data From the Spanish RIBRON Registry.
Oscullo G, Méndez R, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa J, Barreiro E, Prados C, Rodríguez-López JL, de la Rosa-Carrillo D, Martinez-García MÁ. Oscullo G, et al. Arch Bronconeumol. 2025 Apr;61(4):196-202. doi: 10.1016/j.arbres.2025.02.015. Epub 2025 Mar 1. Arch Bronconeumol. 2025. PMID: 40180519 English, Spanish.
INTRODUCTION: There is scarce information about the most used mucolytic drug in bronchiectasis N-acetylcysteine (N-AC). Our objective was to analyze the effect of N-AC with respect to some outcomes in bronchiectasis. ...CONCLUSION: N-AC (in most …
INTRODUCTION: There is scarce information about the most used mucolytic drug in bronchiectasis N-acetylcysteine (N …
Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective.
Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Santus P, et al. J Clin Med. 2024 Jul 15;13(14):4127. doi: 10.3390/jcm13144127. J Clin Med. 2024. PMID: 39064168 Free PMC article. Review.
These properties have sparked interest in its potential for treating chronic lung diseases, including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE), cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF), which are associated with oxidative stres …
These properties have sparked interest in its potential for treating chronic lung diseases, including chronic obstructive pulmonary disease …
Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial.
Qi Q, Ailiyaer Y, Liu R, Zhang Y, Li C, Liu M, Wang X, Jing L, Li Y. Qi Q, et al. Respir Res. 2019 Apr 11;20(1):73. doi: 10.1186/s12931-019-1042-x. Respir Res. 2019. PMID: 30975143 Free PMC article. Clinical Trial.
BACKGROUND: N-acetylcysteine is a classic mucolytic agent. This study aimed to investigate the efficacy of N-acetylcysteine on reducing the risk of exacerbations in bronchiectasis patients. ...Compared with the control group, the volume of 24-h …
BACKGROUND: N-acetylcysteine is a classic mucolytic agent. This study aimed to investigate the efficacy of N-acetylc …
What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.
Oscullo G, Méndez R, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa JL, Barreiro E, Prados C, Rodríguez-Lopez J, de la Rosa D, Martinez-García MÁ. Oscullo G, et al. J Thorac Dis. 2025 Oct 31;17(10):9003-9012. doi: 10.21037/jtd-2025-1159. Epub 2025 Oct 29. J Thorac Dis. 2025. PMID: 41229849 Free PMC article.
BACKGROUND: Bronchiectasis is characterized by excessive respiratory secretions, the management of which is clinically significant. Among the available pharmacological treatments, mucolytics play a pivotal role. N-acetylcysteine (N-AC) is the most comm …
BACKGROUND: Bronchiectasis is characterized by excessive respiratory secretions, the management of which is clinically significant. A …
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study.
Jayaram L, King PT, Hunt J, Lim M, Park C, Hu E, Dousha L, Ha P, Bartlett JB, Southcott AM, Muruganandan S, Vogrin S, Rees MA, Dean OM, Wong CA. Jayaram L, et al. Pulm Pharmacol Ther. 2024 Mar;84:102283. doi: 10.1016/j.pupt.2023.102283. Epub 2023 Dec 22. Pulm Pharmacol Ther. 2024. PMID: 38141851 Clinical Trial.
BACKGROUND: High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised (RCT) studies in patients with COPD, a …
BACKGROUND: High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significa …
Efficacy of N-acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol.
Luo A, Liu X, Hu Q, Yang M, Jiang H, Liu W. Luo A, et al. BMJ Open. 2022 Mar 31;12(3):e053625. doi: 10.1136/bmjopen-2021-053625. BMJ Open. 2022. PMID: 35361640 Free PMC article.
A need for high-quality and specialised care has been highlighted in recent years. N-acetylcysteine (NAC) is a widely used mucolytic agent in respiratory diseases that not only possesses a property to enhance secretion clearance, but also exhibits antioxidant and an …
A need for high-quality and specialised care has been highlighted in recent years. N-acetylcysteine (NAC) is a widely used muc …
The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.
Liao Y, Wu Y, Zi K, Shen Y, Wang T, Qin J, Chen L, Chen M, Liu L, Li W, Zhou H, Xiong S, Wen F, Chen J. Liao Y, et al. BMC Pulm Med. 2022 Nov 7;22(1):401. doi: 10.1186/s12890-022-02202-9. BMC Pulm Med. 2022. PMID: 36344940 Free PMC article.
BACKGROUND: N-acetylcysteine (NAC), which is specifically involved in airway mucus clearance and antioxidation, is recommended by the treatment guideline for non-cystic fibrosis bronchiectasis (NCFB). ...
BACKGROUND: N-acetylcysteine (NAC), which is specifically involved in airway mucus clearance and antioxidation, is recommended …
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. Blasi F, et al. Respir Med. 2016 Aug;117:190-7. doi: 10.1016/j.rmed.2016.06.015. Epub 2016 Jun 16. Respir Med. 2016. PMID: 27492531 Free article. Review.
The aim of this review is to examine current evidence for the use of N-acetylcysteine (NAC) in the treatment of biofilm-related respiratory infections. METHODS: Electronic searches of PUBMED up to September 2015 were conducted, searching for 'biofilm', 'respiratory …
The aim of this review is to examine current evidence for the use of N-acetylcysteine (NAC) in the treatment of biofilm-relate …
The precision medicine strategy to treat COPD pulmonary traits in clinical practice: The role of N-acetylcysteine.
Scioscia G, Baraldi F, Bigoni T, Papi A, Vatrella A, Micheletto C, Foschino Barbaro MP. Scioscia G, et al. Respir Med. 2024 Dec;235:107865. doi: 10.1016/j.rmed.2024.107865. Epub 2024 Nov 15. Respir Med. 2024. PMID: 39549856 Review.
This work reviews the TT strategy in COPD, giving special attention to the most relevant pulmonary traits, such as frequent productive cough, chronic bronchitis, type 2 inflammation, neutrophilic inflammation, lung hyperinflation, bronchiectasis, exacerbations and non-reve …
This work reviews the TT strategy in COPD, giving special attention to the most relevant pulmonary traits, such as frequent productive cough …
Mucolytics for bronchiectasis.
Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Wilkinson M, et al. Cochrane Database Syst Rev. 2014 May 2;2014(5):CD001289. doi: 10.1002/14651858.CD001289.pub2. Cochrane Database Syst Rev. 2014. PMID: 24789119 Free PMC article.
BACKGROUND: Bronchiectasis is predominantly an acquired disease process that represents the end stage of a variety of unrelated pulmonary insults. ...It has been suggested that with widespread use of high-resolution computed tomography, more bronchiectasis diagnoses …
BACKGROUND: Bronchiectasis is predominantly an acquired disease process that represents the end stage of a variety of unrelated pulmo …
48 results